CD70 Knockout Cell Line (HEK 293)

The choice depends on whether you are studying CD70's role as a TNF family ligand or modeling its emerging applications as an AML and renal cell carcinoma therapy target. The Knockout line is the standard tool for asking whether CD70 is required for these processes — CD70 is a type II transmembrane TNF family ligand that binds CD27 (TNFRSF7) on T cells, B cells, and NK cells, driving co-stimulation and survival signaling; CD70 is highly expressed on activated immune cells, but importantly is aberrantly expressed on AML, lymphoma, and renal cell carcinoma. Overexpression is useful for studying CD70 in heterologous expression contexts. For cancer immunotherapy research, the EDITGENE CD70 Knockout in HEK293 is uniquely valuable — CD70 is one of the most clinically advanced AML/RCC therapy targets. Rescue with wild-type CD70 is the standard specificity control. The knockout is a critical specificity tool for ⭐ cusatuzumab (ARGX-110, anti-CD70 antibody in clinical development for AML — has shown promising activity), allogeneic CD70-CAR-T cells (CTX130 for RCC and T-cell lymphoma), CD70-ADCs (SGN-CD70A, MDX-1203), and emerging CD70-targeted approaches — CD70 is particularly attractive because of its restricted normal-tissue expression.

Primary applications: • CD27 binding: CD27-Fc binding analysis in CD70-null cells. • CD70-targeted therapy specificity: critical genetic control for ⭐ cusatuzumab (ARGX-110, anti-CD70 antibody in AML clinical development), CTX130 (allogeneic CD70-CAR-T for RCC and T-cell lymphoma), SGN-CD70A and MDX-1203 (CD70-ADCs). • T cell co-stimulation: in heterologous T cell-relevant contexts, CD27-mediated T cell co-stimulation following CD70 engagement. • Cancer biology: in heterologous AML/RCC contexts, characterization of CD70's role in tumor immune evasion. EDITGENE recommends this model as the gold-standard genetic specificity control for the rapidly advancing CD70-targeted AML and RCC therapy field.

Yes. CD70 rescue experiments require attention to type II TNF family ligand architecture: • Construct design: use a codon-modified CD70 sequence with a small intracellular N-terminal tag (FLAG, HA) — CD70 is a type II transmembrane TNF family ligand with intracellular N-terminus and extracellular C-terminal TNF homology domain; N-terminal tag preserves extracellular ligand region. • Surface localization validation: confirm plasma membrane CD70 by cell surface staining before anti-CD70 compound testing. • Trimerization considerations: TNF family ligands function as trimers — rescue should preserve trimerization-competent CD70. • Functional readout: rescue should restore CD27-binding activity and anti-CD70 antibody/CAR-T/ADC compound binding. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation for systematic CD70-targeted therapy validation.